Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

ANI Pharmaceuticals, Inc. (ANIP) had Revenue of $486.82M for the most recently reported fiscal year, ending 2023-12-31.

Quarterly Annual

Figures for fiscal year ending 2023-12-31

Income Statement Financials
Revenue	$486.82M
Net Income	$17.15M
Cost of Goods Sold	$181.51M
Gross Profit	$305.30M
Operating Expenses	$439.85M
Operating Income	$46.97M
Non-Operating Income/Expense	$-27.10M
Pre-Tax Income	$19.87M
Normalized Pre-Tax Income	$19.87M
Income after Taxes	$18.78M
Income from Continuous Operations	$18.78M
Consolidated Net Income/Loss	$18.78M
Normalized Income after Taxes	$18.78M
EBIT	$46.97M
EBITDA	$106.76M
Weighted-Average Shares Outstanding (Basic)	18.00M
Weighted-Average Shares Outstanding (Diluted)	18.19M
Earnings per Share (EPS) (Basic)	$0.86
Earnings per Share (EPS) (Diluted)	$0.85
Balance Sheet Financials
Current Assets	$519.82M
Property, Plant, and Equipment	$44.59M
Long-Term Assets	$384.61M
Total Assets	$904.42M
Current Liabilities	$145.48M
Long-Term Debt	$284.82M
Long-Term Liabilities	$301.35M
Total Liabilities	$446.82M
Common Equity	$432.75M
Tangible Shareholders Equity	$220.37M
Shareholders Equity	$457.60M
Common Shares Outstanding	20.48M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$118.96M
Cash Flow from Investing Activities	$-18.51M
Cash Flow from Financial Activities	$67.44M
Beginning Cash	$53.23M
End Cash	$221.12M
Increase/Decrease in Cash	$167.89M
Stock-Based Compensation	$20.65M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	$-1.62M
Fundamental Metrics & Ratios
Current Ratio	3.57
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.38
Debt to Equity Ratio	0.62
Gross Margin	62.71%
Operating Margin	9.65%
EBIT Margin	9.65%
EBITDA Margin	21.93%
Pre-Tax Profit Margin	4.08%
Profit Margin	3.52%
Free Cash Flow	$110.09M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.54
Inventory Turnover	1.63
Receiveable Turnover	3.00
Days Sales in Receivables	121.52
Return on Equity	4.34%
Return on Tangible Equity	8.52%
Return on Assets	2.08%
Return on Investments	2.53%
Book Value Per Share	$22.35
Free Cash Flow per Share	$6.05
Operating Cash Flow per Share	$6.54

Data from Zacks Investment Research, Inc.